Evidence map›Paper›PMID 28168567›Full record

Trial reportInternational ophthalmology2018

Extended targeted retinal photocoagulation versus conventional pan-retinal photocoagulation for proliferative diabetic retinopathy in a randomized clinical trial.

Homayoun Nikkhah, Hossein Ghazi, Mohammad Reza Razzaghi, Saeed Karimi, Alireza Ramezani, Masoud Soheilian

2 registry-linked trialsAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01232179 phase2unknown statusnot on this map

Comparison Between Result and Side Effects of Treatment of Prolifrative Diabetic Retinopaty by Conventional and Extended Targeted Pan Retinal Photocoagolation

TypeinterventionalSponsorShahid Beheshti University of Medical SciencesRan2010 to 2011ConditionsProiriftrative Diabetic RetinopathyArmsconventional prp, targeted prp
NCT04674254 phase4completednot on this mapstarted 2021, after this paper: background citation

Macular Perfusion Changes in Proliferative Diabetic Retinopathy Following Anti-VEGF Therapy Versus Targeted and Pan-retinal Photocoagulation Using Optical Coherence Tomography Angiography

TypeinterventionalSponsorCairo UniversityRan2021 to 2023Enrolled43ConditionsProliferative Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression, Diabetic RetinopathyArmsBevacizumab Injection, Targeted retinal photocoagulation, Standard pan-retinal photocoagulation
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Different lasers and techniques for proliferative diabetic retinopathy.The Cochrane database of systematic reviews · 2018
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Observational
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Peripheral retinal lesions in diabetic retinopathy on ultra-widefield imaging.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Homayoun NikkhahTorfe and Imam Hossein medical centers, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hossein GhaziOphthalmology Department and Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammad Reza RazzaghiOphthalmology Department and Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Saeed KarimiOphthalmology Department and Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Alireza RamezaniTorfe and Imam Hossein medical centers, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Masoud SoheilianOphthalmology Department and Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. masoud_soheilian@yahoo.com.
Shahid Beheshti University of Medical Sciences · IRImam Hossein Hospital · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo determine the clinical efficacy of extended targeted retinal photocoagulation (ETRP) compared to conventional panretinal photocoagulation (CPRP) in proliferative diabetic retinopathy (PDR).

methodsIn a single-masked randomized clinical trial, 270 eyes of 234 patients with naïve early or high-risk PDR were randomly assigned to receive either CPRP or ETRP (135 eyes, each treatment arm). Best-corrected visual acuity (BCVA) measurement, fundus examination, wide-field fluorescein angiography (WFFA) and optical coherence tomography were carried out before and 3 months after retinal photocoagulation. Primary outcome was early PDR regression, specified as reduction in retinal neovascularization based on WFFA at 3 months. Secondary outcomes were BCVA and central macular thickness (CMT) changes.

resultsThere were significantly more high-risk PDR eyes in ETRP group compared to CPRP (109 and 94 eyes, respectively, P = 0.04). Early PDR regression occurred in 71.9 and 64.4% of eyes in the ETRP and CPRP groups, respectively (P = 0.19). The mean number of applied laser spots in the ETRP was significantly fewer than CPRP (1202 vs. 1360, respectively, P < 0.001). Mean BCVA at baseline and 3 months post-laser were 0.37 ± 0.26 and 0.47 ± 0.19 logMAR in the ETRP arm, respectively. In the CPRP arm these values were 0.40 ± 0.27 and 0.47 ± 0.24 logMAR, respectively. Although mean BCVA decreased significantly in both treatment arms (ETRP P < 0.001, CPRP P = 0.009), the difference was not significant between arms (P = 0.68). CMT increased significantly in both groups (ETRP 41.08 μm, P < 0.001, CPRP 33.31 μm, P < 0.001). Nevertheless, the difference between the groups was not significant (P = 0.26).

conclusionsETRP with fewer number of laser spots may be an appropriate alternative to CPRP in PDR regression at least through 3 months. CLINICAL TRIAL: GOV REGISTRATION NUMBER: NCT01232179.

Indexed as

Visual AcuityAdultAgedDiabetic RetinopathyEquipment DesignFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansImaging, Three-DimensionalLaser CoagulationLight CoagulationMaleMiddle AgedRetinaExtended targeted retinal photocoagulationPanretinal photocoagulationProliferative diabetic retinopathy

Identifiers

PMID28168567
OpenAlexW2586088993

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.